# MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

> **NCT00070837** · PHASE1,PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 46 (—)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** MLN2704 (DM1 conjugated monoclonal antibody MLN591)

## Key facts

- **NCT ID:** NCT00070837
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 46 (—)
- **Last updated:** 2007-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070837, "MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00070837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*